Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elekta AB stock logo
EKTAY
Elekta
$5.01
+1.2%
$4.98
$4.36
$7.13
$1.85B1.1913,577 shs2,470 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$89.47
-0.4%
$96.84
$77.10
$163.71
$5.13B0.78960,556 shs579,647 shs
Teleflex Incorporated stock logo
TFX
Teleflex
$120.24
-0.4%
$117.93
$108.90
$249.90
$5.31B1.08795,834 shs529,205 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$125.65
-1.5%
$123.66
$55.00
$177.37
$4.28B2.091.34 million shs563,396 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elekta AB stock logo
EKTAY
Elekta
0.00%+0.95%+0.03%-8.64%-23.71%
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+6.04%-8.02%-6.12%-29.44%
Teleflex Incorporated stock logo
TFX
Teleflex
0.00%+2.05%+8.83%-5.57%-49.43%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.00%+11.40%+16.08%+4.46%-25.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elekta AB stock logo
EKTAY
Elekta
N/AN/AN/AN/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
4.4106 of 5 stars
3.44.00.04.42.91.70.6
Teleflex Incorporated stock logo
TFX
Teleflex
4.8773 of 5 stars
2.05.02.53.94.13.32.5
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.7008 of 5 stars
2.42.00.00.03.32.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elekta AB stock logo
EKTAY
Elekta
2.00
HoldN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
2.85
Moderate Buy$127.4242.42% Upside
Teleflex Incorporated stock logo
TFX
Teleflex
2.00
Hold$141.5717.74% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.78
Moderate Buy$123.00-2.11% Downside

Current Analyst Ratings Breakdown

Latest EKTAY, TFX, GKOS, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/1/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$130.00 ➝ $135.00
8/1/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$130.00 ➝ $135.00
8/1/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$137.00 ➝ $131.00
8/1/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $123.00
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$130.00
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$86.00 ➝ $92.00
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$125.00 ➝ $134.00
7/16/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$150.00 ➝ $130.00
7/15/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetSector Perform ➝ Sector Perform$145.00 ➝ $130.00
7/15/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$129.00 ➝ $142.00
(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elekta AB stock logo
EKTAY
Elekta
$1.71B1.08$0.62 per share8.09$2.19 per share2.29
Glaukos Corporation stock logo
GKOS
Glaukos
$432.95M11.85N/AN/A$13.91 per share6.43
Teleflex Incorporated stock logo
TFX
Teleflex
$3.05B1.74$25.26 per share4.76$92.11 per share1.31
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M9.70$1.62 per share77.52$6.81 per share18.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elekta AB stock logo
EKTAY
Elekta
$22.37M$0.05100.2611.66N/A1.15%11.55%3.75%8/27/2025 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$1.65N/AN/AN/A-21.43%-8.59%-6.61%11/3/2025 (Estimated)
Teleflex Incorporated stock logo
TFX
Teleflex
$69.68M$4.2528.297.921.686.31%15.08%8.85%10/30/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.9365.1087.87N/A13.49%28.02%8.64%10/27/2025 (Estimated)

Latest EKTAY, TFX, GKOS, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q2 2025
Teleflex Incorporated stock logo
TFX
Teleflex
$3.36$3.73+$0.37$2.77$771.53 million$780.90 million
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26-$0.24+$0.02-$0.34$115.49 million$124.12 million
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48$0.92+$0.44$0.92$146.64 million$157.37 million
5/28/2025Q4 2025
Elekta AB stock logo
EKTAY
Elekta
$0.13$0.11-$0.02-$0.10$507.19 million$503.22 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elekta AB stock logo
EKTAY
Elekta
$0.122.39%N/A240.00%N/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
$1.361.13%N/A32.00%N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A

Latest EKTAY, TFX, GKOS, and TMDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/31/2025
Teleflex Incorporated stock logo
TFX
Teleflex
quarterly$0.341.19%8/15/20258/15/20259/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elekta AB stock logo
EKTAY
Elekta
0.70
1.09
0.86
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
5.51
4.69
Teleflex Incorporated stock logo
TFX
Teleflex
0.42
2.41
1.44
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.61
9.86
9.17

Institutional Ownership

CompanyInstitutional Ownership
Elekta AB stock logo
EKTAY
Elekta
N/A
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Elekta AB stock logo
EKTAY
Elekta
41.28%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
Teleflex Incorporated stock logo
TFX
Teleflex
1.40%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elekta AB stock logo
EKTAY
Elekta
4,718368.59 million216.44 millionNot Optionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.35 million53.68 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,10044.19 million43.57 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21034.09 million31.70 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elekta stock logo

Elekta OTCMKTS:EKTAY

$5.01 +0.06 (+1.22%)
As of 01:52 PM Eastern

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Glaukos stock logo

Glaukos NYSE:GKOS

$89.47 -0.39 (-0.44%)
Closing price 03:59 PM Eastern
Extended Trading
$91.90 +2.44 (+2.73%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Teleflex stock logo

Teleflex NYSE:TFX

$120.24 -0.44 (-0.36%)
Closing price 03:59 PM Eastern
Extended Trading
$119.92 -0.32 (-0.27%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$125.65 -1.90 (-1.49%)
Closing price 04:00 PM Eastern
Extended Trading
$126.03 +0.38 (+0.30%)
As of 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.